MedWatch

Novo Nordisk on new key opportunity: We are going into launch mode

The Danish drug group Novo Nordisk expects to launch the new hope of the company’s pipeline in the US by the beginning of 2018. Launches in Japan and Europe will follow later in the year. According to CEO Lars Fruergaard Jørgensen, the weekly GLP-1 analogue provides Novo with a golden opportunity to take on Trulicity, the rival drug from Eli Lilly.

Foto: Novo Nordisk/PR

Novo Nordisk’s business is under pressure, in the smaller biopharma segment as well as the core business of diabetes treatment. The 2017 Q3 sales dropped in both business segments.

However, the Danish drug group has a solution on the way.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier